Navigation Links
OctreoPharm Sciences Receives Orphan Drug Designation for SOMscan® for the Diagnosis of Neuroendocrine Tumours
Date:10/12/2011

BERLIN, October 12, 2011 /PRNewswire/ --

OctreoPharm Sciences GmbH, a Berlin based specialist for radiopharmaceuticals, announced today that the European Medicines Agency has granted Orphan Drug status to OctreoPharm Sciences product SOMscan® for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.

The Orphan Drug status entitles OctreoPharm Sciences to ten year market exclusivity in Europe following marketing approval for SOMscan®. The designation also provides for special benefits, including possible exemptions in certain regulatory fees during development.

"We are proud to have received this Orphan Drug Designation for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours" said Dr. Hakim Bouterfa, Managing Director and Head of R&D. Udo Blaseg, Managing Director and Head of Operations added: "This designation is an important step for a new and heavily improved diagnostic and staging tool for a seriously debilitating and potentially lethal disease."

About SOMscan™

SOMscan is a new Gallium-68-labeled radioactive contrast agent for positron emission tomography with the potential to detect neuroendocrine tumors currently in Phase I. It binds to four out of five specific tumor receptor subtypes on the surface of neuroendocrine tumors. This may allow detection of neuroendocrine tumors which previously escaped discovery in imaging. The diagnosis of neuroendocrine tumors with SOMscan has the potential to be faster, more accurate, more reliable and more specific.

About OctreoPharm Sciences GmbH

OctreoPharm Sciences GmbH is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control of tumors. The company intends to acquire licenses for other product candidates as well. OctreoPharm Sciences is in particular on the lookout for collaborations with pharmaceutical companies which focus on products for personalized medicine and new therapeutic agents.

Contact:
Udo Blaseg
OctreoPharm Sciences GmbH
Robert-Rössle-Straße 10
13125 Berlin
Phone:  +49(0)30-9489-3360
eMail:  info@octreopharm.com



'/>"/>
SOURCE OctreoPharm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OctreoPharm Sciences GmbH Granted Global and Exclusive License for Oncology Diagnostic Product
2. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
3. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
4. SV Life Sciences Appoints Veteran Diagnostics Professional Dr. Heiner Dreismann as Venture Partner
5. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
6. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
7. Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
8. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
9. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
10. BD Biosciences Introduces New Device Designed to Increase Cell Growth and Cell Culture Productivity
11. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
Breaking Medicine News(10 mins):